Oncology

Ramucirumab improved overall survival and progression-free survival in patients with advanced hepatocellular carcinoma who have a high alpha-fetoprotein.

Top news of the week from Specialty Pharmacy Times.

The EGFR/TNF inhibitor treatment effectively blocks the tumor necrosis factor escape route for non-small cell lung cancer.

At the 2018 National Community Oncology Dispensing Association (NCODA) Spring Summit, Julianne Orr, PharmD, from the Indiana University Health Simon Cancer Center, discusses how pharmacists can help patients who are transitioning from an infusion product to an oral chemotherapy.

US report indicates new drivers of death have emerged over time and have continued to unequally affect residents at the state level.

The therapy is a combination of a checkpoint drug, nivolumab, and a new immune stimulation drug, ALT-803.

New drug shows promising signs of delaying the development of existing breast and lung cancers. .

Pediatric patients treated with larotrectinib in a clinical trial demonstrated a 93% response rate.

A novel chimera targets the growth factors responsible for certain types of breast cancer.

According to the study, patients who take a reduced dose of abiraterone with a low-fat meal may cut costs by as much as $300,000.

Triple-negative and HER2-positive breast cancers may be unlikely to develop lymph node metastases.

Over the years, a number of landmark clinical studies on the management of breast cancer have been published, sharpening how patients are treated today.

Overweight patients with BRCA mutations may be more likely to develop breast cancer.

Top news of the week from Specialty Pharmacy Times.

Over the years, a number of landmark clinical studies on the management of breast cancer have been published, sharping how patients are treated today.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Breast cancer treatments may affect men differently than women.

Breast cancer survivors and insurance companies could gain a better understanding of mortality risk with a new model.

Chronic infection with hepatitis C virus is the leading cause of hepatocellular carcinoma.

Fuel source of cancer cells could impact their efficacy of CAR-T cell therapies for pediatric patients.

Combining Tecentriq with Avastin shows promise extending survival in patients with non-small cell lung cancer.

AbbVie will not seek accelerated approval of Rovalpituzumab Tesirine as a third-line therapy for small cell lung cancer.

The addition of atezolizumab (Tecentriq) to chemotherapy may improve outcomes for patients with advanced non-small cell lung cancer.

A PET scan could quickly indicate whether EGRF-targeted therapy would be beneficial to patients with non-small cell lung cancer.

Biosimilars for rituximab, trastuzumab, and bevacizumab are currently approved for use in the European Union.

Prostate cancer is the leading cancer in men, with about 1 in 8 developing it in his lifetime.

Olaparib (Lynparza) double objective response rate compared with other breast cancer drugs.